Durvalumab is a selective human immunoglobulin G1 monoclonal antibody against PD-L1, and tremelimumab is a selective human immunoglobulin G2 monoclonal antibody binding to cytotoxic T-lymphocyte-associated antigen-4; the combination of durvalumab and tremelimumab has shown preliminary antitumor efficacy in locally advanced or metastatic NSCLC, with a manageable tolerability [87]. Here, CD274 is linked to non-small cell lung carcinoma.